February 19-22, 2025 The research team at Gastroenterology Department led by Prof Qian CAO and Dr Jing LIU at Sir Run Run Shaw Hospital in Hangzhou China, has recently achieved notable progress in a significant study, which revealed leukocyte adhesive function as a potential predictive biomarker for response to vedolizumab therapy in biologic-naïve Crohn’s disease patients. These findings were presented via a poster at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO 2025), garnering widespread attention. Crohn’s disease is a chronic inflammatory bowel disease. The goals of its treatment are to reduce inflammation, control symptoms, and improve patients’ quality of life. Vedolizumab, a commonly used biological agent, works by blocking the migration of leukocytes to the gut. However, not all